Jean-Charles Soria to Immunotherapy
This is a "connection" page, showing publications Jean-Charles Soria has written about Immunotherapy.
Connection Strength
1.174
-
[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge]. Med Sci (Paris). 2017 Jun-Jul; 33(6-7):563-564.
Score: 0.258
-
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017 03 13; 15(1):55.
Score: 0.252
-
Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018 12; 15(12):748-762.
Score: 0.071
-
Bull Cancer. 2018 Dec; 105 Suppl 1:S59-S67.
Score: 0.071
-
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018 05; 95:68-74.
Score: 0.068
-
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer. 2017 12; 87:65-74.
Score: 0.066
-
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 05; 359(6371):91-97.
Score: 0.066
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
Score: 0.065
-
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017 10; 84:212-218.
Score: 0.065
-
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
Score: 0.064
-
JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. Cancer Discov. 2017 02; 7(2):128-130.
Score: 0.063
-
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018 09; 101:160-164.
Score: 0.017
-
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 03 20; 36(9):850-858.
Score: 0.017
-
[Hodgkin lymphoma: Current and future therapeutic strategies]. Bull Cancer. 2018 Jan; 105(1):81-98.
Score: 0.017
-
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Ann Pathol. 2016 Jan; 36(1):94-102.
Score: 0.015